AbbVie’s $10.1 billion deal to buy ImmunoGen values the stock at a 95% premium
November 30, 2023 at 08:26 AM EST
ImmunoGen's stock rocketed to the highest price seen in two decades after the biotechnology company announced an agreement to be acquired buy AbbVie in a cash deal valued at $10.1 billion.
